Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-03-16

FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

The FDA approved a supplemental application to add an extended-release formulation of desvenlafaxine succinate (Pristiq Extended-Release) by Wyeth Pharmaceutica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PRISTIQ EXTENDED-RELEASE (Desvenlafaxine succinate)

Snippet

SUPPL AP for PRISTIQ EXTENDED-RELEASE (DESVENLAFAXINE SUCCINATE)